Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.

NCT Number	NCT07675044
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: Sanofi
Conditions	Asthma, Type 2 Asthma
Enrollment	200 participants
Start Date	2026-07
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-30